Pular para o conteúdo principal
Ranking Invest

OGN - Organon & Co.

Segmento: HealthcareOrganon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Análise Ranking Invest

Valor de Mercado
$ 3.63 Bi
IVR
0.73Índice proprietário de comparação relativa: 0,73.
IVR2
0.66Leitura proprietária complementar: 66%.
MLL
0.66Leitura proprietária complementar: 66%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 1.01 Bi

Dívida Líquida

$ 7.50 Bi

L4T

$ 209.00 Mi

MM4T

3.33%

Indicadores Básicos

ROE

20.78%

Índices de Previsibilidade

Receita Líquida

B0.03

Lucro

D0.64

Margem

D0.64

Índices de Tendência

Receita Líquida

D-0.71

Lucro

E-4.36

Margem

F-4.42

Índices de Endividamento

DIV/PAT

7.45

DIV/L4T

35.86

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.